Presenting Sponsor: Takeda
Subscribe to BloodStream Podcast: Link
BioMarin plans return to FDA with updated data on hemophilia gene therapy (BioPharmaDive): Link
BioMarin's hemophilia A gene therapy hits goal in phase 3, teeing up FDA filing despite durability doubts (Fierce Biotech): Link
Connect with BloodStream Media: